Expanded Access Listings

Pfizer

Treatment Use Study With Sunitinib (SU011248) For Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma

The primary objective of this protocol is to provide access to SU011248 treatment forpatients with metastatic RCC who are ineligible for participation in ongoing SU011248clinical studies and have the potential to derive clinical benefit from treatment withSU011248 based on the judgment of the investigator.

Boehringer Ingelheim

Tipranavir Expanded Access Program (EAP) in PI-experienced Patients With HIV-1 Infection

This study was designed to provide early access to and evaluate the safety of TPV/r inPI-experienced patients with HIV-1 infection.

Pfizer

A Treatment Protocol for Patients With Gastrointestinal Stromal Tumor (GIST) Who May Derive Benefit From Treatment With SU011248

The purpose of this study is to permit access to SU011248 for treatment use by patientswith GIST given the following conditions: a) patients undergo screening, but are noteligible for participation in ongoing clinical studies such as A6181004; AND b) patientshave GIST which standard treatments have not been able to control with acceptabletoxicity AND c) patients have the potential to derive clinical benefit from treatmentwith SU011248.

Silver Creek Pharmaceuticals

Ionis Pharmaceuticals, Inc.

Olezarsen Early Access Program for Patients With Familial Chylomicronemia Syndrome (FCS)

The purpose of the Expanded Access Program is to provide pre-approval access of olezarsento eligible patients with Familial Chylomicronemia Syndrome (FCS).

Neuraptive Therapeutics Inc.

NTX-001 to Repair Peripheral Nerve Transection(s)

The proposed use of NTX-001 for transections of upper extremity and facial peripheralnerves, acutely or planned.

Oblato, Inc.

Expanded Access to OKN-007 for Patients With Diffuse Midline Glioma, H3 K27-altered

To provide OKN-007 for compassionate use in patients with diffuse midline glioma, H3K27-altered (DMG), including diffuse intrinsic pontine glioma (DIPG), pediatric and youngadult patients with high-grade diffuse midline glioma will be treated under thisIntermediate-sized expanded access treatment protocol.

Matrix Biomed, Inc.

Treatment of Metastatic Cancer in Terminally Diagnosed Patients

The objective is to provide terminally diagnosed patients with a last line of treatmentwhile improving overall quality of life. Tempol can be added to any chemotherapy regimento potentially reduce side effects and overcome chemoresistance.

W.L.Gore & Associates

Evaluation of the GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis in the Treatment of the Thoracoabdominal and Pararenal Aortic Aneurysms (TAMBE)

Expanded access tothe GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis is safe andeffective in the treatment of thoracoabdominal and pararenal aneurysms.

DBV Technologies

Expanded Access Protocol of Viaskin® Peanut (DBV712) in Peanut-allergic Children

This is an open label expanded access program for male and female patients 2 years orolder, to provide continued desensitization treatment with DBV712 250 mcg.